Transaction #12675 · Form 4 · 0001438133-25-000221
TANDEM DIABETES CARE INC · Stock award · Restricted Stock Unit
TANDEM DIABETES CARE INC · Transacted November 7, 2025 · Filed November 25, 2025
What does this filing report?
An SEC Form 4 filing for TANDEM DIABETES CARE INC records a stock award involving Restricted Stock Unit on November 7, 2025. The reported quantity was 20,242. The filing date is November 25, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- TANDEM DIABETES CARE INC
- Company CIK
- 0001438133
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 20,242
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 20,242
- Ownership description
- Not reported
- SEC acceptance time
- Nov 25, 2025, 4:10 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Beaver Sandra ↗
Director
CIK 0001944884
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 20,242
- Conversion / exercise price
- Not reported
- Exercise date
- Not reported
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- Awarded on November 7, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
- F2
- Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
- F3
- RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 11/15/2026, and the remaining shares shall vest in two (2) equal annual installments thereafter.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.